Cardiac surgical outcomes in abdominal solid organ (renal and hepatic) transplant recipients: a case-matched study

Rajiv Sharmaa*, Carmel Hawleyb, Raylene Griffinc, Julie Mundyf, Paul Petersi and Pallav Shaha

a Department of Cardiothoracic Surgery, Princess Alexandra Hospital, Brisbane, Australia
b Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia
c Corresponding author. Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD 4102, Australia. Tel: +61-07-31767675; fax: +61-07-31766954; e-mail: docrajivsharma@gmail.com (R. Sharma).

Received 10 February 2012; received in revised form 13 May 2012; accepted 24 May 2012

Abstract

OBJECTIVES: This study aims to investigate the outcomes of cardiac surgery in patients with abdominal solid organ transplants and to compare them with the case-matched population undergoing cardiac surgery.

METHODS: Data from all transplant recipients abdominal solid organ transplant (ASOT) N = 36 (30 renal and 6 hepatic) who underwent cardiac surgery in a single centre during the period from January 1997 to December 2010 were collected from hospital transplant registries and the cardiac database. The transplant recipients were case matched (CM) with 104 patients in terms of the variables of age, sex and the type of cardiac surgery. Follow-up data were obtained from medical records and by a set of questionnaire through telephonic interviews.

RESULTS: Follow-up times were 4.5 ± 3.2 and 3.9 ± 3.2 years in the transplant and CM groups, respectively. Follow-up in the transplant group was 100%. There was no 30-day mortality in the transplant group. Thirty-day combined major morbidities were 9% in the matched group vs 11% in the transplant patients (P = 0.6). Median length of stay was 6 days (inter-quartile range, IQR 5.9) for ASOT vs 5 days (IQR 4.6) for CM (P < 0.01). New dialysis was 8.3% in transplant patients compared with 0.96% in the matched population, while infection was 16.66 vs 0.42% in the CM cohort. There was no allograft failure/dysfunction at the time of death or latest follow-up. Late deaths were 8 of 36 (22%) in ASOT vs 6 of 104 (6%) in CM. Infection (63%) was the most frequent major cause of death in transplant patients. One-, 2-, 5- and 10-year survivals for ASOT vs CM were 94, 88, 80, 59 vs 99, 99, 91, 85%, respectively. Multivariate predictors of mortality were increasing age (hazard ratio, HR 1.1, 95% confidence interval, CI 1.04–1.18; P = 0.003) and solid organ transplantation (HR 3.44, CI 1.19–9.98; P = 0.023).

CONCLUSIONS: Cardiac surgery can be performed in patients with abdominal solid organ transplant recipients with acceptable early morbidity and mortality. However, long-term survival in transplant patients is poor. Infection remains the most common cause of death.

Keywords: Renal transplantation • Liver transplantation • Organ transplantation • Cardiac surgical procedures/mortality

INTRODUCTION

A rapid improvement in transplant medicine in the last few decades has seen more people receiving transplants. Transplant patients innately have an increased burden of co-morbidities per se. The milieu interior is further deleteriously affected by altered immune status and the multitude of drugs administered to them. Consequently, it is not surprising that the relative risk of cardiovascular events and the absolute risk of cardiovascular death are increased in allograft recipients compared with the age-matched population without transplants [1]. However, despite their increasing age and higher risk profile, excellent early survival has been reported in both hepatic [2] and renal [3] transplant recipients. This ever-expanding cohort has a unique course of pathophysiological events. Cardiopulmonary bypass is deleterious to even the native organs by virtue of not being physiological, therefore, it would also adversely affect the transplanted organs when they are exposed to cardiopulmonary bypass during cardiac surgery. In addition, the altered post-transplant physiology (e.g. by immunosuppression) would affect the cardiac surgical outcomes. Consequently, it has become important to study the course of existing cardiovascular disease and the evolution and progress of new cardiovascular disease in solid organ transplant recipients and to study the effect of disease management algorithms on the allografts, compared with the general population undergoing cardiac surgery. The new set of problems arising from this surrogate disease poses interesting and hitherto unanswered questions.

This is the first study addressing the short- and long-term outcomes of cardiac surgery in solid organ transplant recipients in terms of comparative analysis with a case-matched (CM) population undergoing cardiac surgery. It aims to address the above-mentioned issues in an effort to modify treatment, guide informed consent, help in resource allocation and give directions in future health policy planning.
MATERIALS AND METHODS

The study was approved by the institutional ethics committee. All patients who had renal or hepatic transplant in our and other hospitals and went on to have cardiac surgery at our university hospital were included in our study. This comprised patients receiving allografts from 1984 to December 2010 abdominal solid organ transplant (ASOT). Each of these patients were CM in a ratio of 1:3 for the variables of age, sex and type of operation performed.

Data were collected in a prospective manner from the separate renal and hepatic transplant registries of the hospital.

Demographic, cardiac, renal and hepatic variables

The cardiac surgical database provided preoperative information of patient demographics. Data were collected for the patient age at the time of cardiac surgery, gender and preoperative morbidities, e.g. diabetes, hypertension, history of smoking, family history, dyslipidaemia, cerebrovascular disease, peripheral vascular disease and chronic obstructive pulmonary disease (COPD). Following this, the severity of cardiovascular disease was risk stratified by using logistic EuroSCORE. Cardiovascular variables like angina, dyspnoea, New York Heart Association (NYHA) and Canadian Cardiovascular Society class at the time of cardiac surgery and follow-up, previous myocardial infarction and previous cardiac intervention were recorded. Clinical history including any change in the cardiovascular drug regimen during cardiac surgery and routine laboratory test values were recorded.

Specific data regarding transplant surgery, e.g. reason for transplant of particular organ, type of transplant viz. cadaveric or live donor, type of immunosuppressant, change of immunosuppression regimen in the cardiac surgical perioperative period, the duration of immunosuppression and complete allograft follow-up data were obtained from specific records kept in the renal and hepatic transplant facilities and the transplant registries.

The operative data were collected detailing various procedures, type of conduits and valve prosthesis, cardiopulmonary bypass and cross-clamp times, previous cardiovascular interventions and repeat cardiovascular interventions.

Patients. The study period spanned 13 years from January 1997 to December 2010. All patients who underwent cardiac surgery in our hospital after receiving allograft in our hospital or elsewhere (N = 36) were included in the study. This formed the transplant group, 30 renal transplant patients (83.4%) formed Group I, while 6 hepatic transplant patients (16.6%) comprised Group II. Together, they added up to a total of 36 transplant patients comprising Group III. The CM population of 104 patients formed Group IV. These 36 patients were CM with the variables of age, sex and type of cardiac surgery. This comprised the CM group (N = 104). One patient who had aortic and tricuspid valve repair with coronary artery bypass graft surgery could not be CM, thereby explaining the discrepancy in the number of the CM cohort (Table 1).

Operative procedure. All procedures were done on cardiopulmonary bypass using blood cardioplegia except four in the transplant group (one pericardiectomy and three off-pump left internal thoracic artery-left anterior descending artery). In all patients operated on cardiopulmonary bypass, the perfusion pressures were kept at a mean of 75–80 mmHg aiming at perfusing the allograft optimally and keeping an adequate safety margin in perfusion should the perfusion pressures fall in any eventuality.

Antibiotic prophylaxis. Antibiotic prophylaxis was given as per the unit protocol with thrice daily doses of cephazolin starting at induction and continued to the first postoperative day. However, patients with endocarditis received antibiotics as indicated by the blood cultures. Infectious disease physicians were consulted for advice regarding antibiotic usage where appropriate.

Immunosuppression. All patients except 4 were on immunosuppression, even those with failed transplants. According to the cardiothoracic and transplant team’s protocol, no change in immunosuppression was effected; however, all patients received 100 mg of hydrocortisone as a stress dose immediately after induction, but none postoperatively. No CM patient was on immunosuppression for any reason. The preoperative immunosuppression was restarted as soon as possible postoperatively, on resumption of oral intake or through a nasogastric tube.

Monitoring of allograft function. In the perioperative period, routine investigations were carried out. Routinely, full blood counts, coagulation profile, urea, creatinine, serum sodium, potassium, chloride and magnesium levels and liver enzymes viz. aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase and alkaline phosphatase (ALP) on Day 0, 1, 2 and Day 4 were measured. If the patients stayed more than 5 days another set of tests were performed immediately before

<table>
<thead>
<tr>
<th>Table 1: Type of cardiac surgery in four groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 renal transplant recipients (N = 30) (%)</td>
</tr>
<tr>
<td>CABG</td>
</tr>
<tr>
<td>15 (50)</td>
</tr>
<tr>
<td>3 (50)</td>
</tr>
<tr>
<td>18 (50)</td>
</tr>
<tr>
<td>51 (49)</td>
</tr>
</tbody>
</table>

P = 0.99 comparing differences between all groups (Fisher’s exact test). CABG: coronary artery bypass graft.
discharge. Strict intake and output balance were maintained. The transplant medicine team was involved in the clinical management of the transplant cohort where appropriate.

**Discharge.** All patients were discharged home in routine practice. Patients requiring rehab or input from other medical teams continued to be under the primary care of the surgical team.

**Outcomes variables**

Postoperative information comprised, but was not limited to, 30-day (in-hospital) morbidity and mortality viz., it also included the use of blood products, ventilation data, new renal failure, re-admission for cardiovascular or transplant organ dysfunction etc. The details about the renal and hepatic dysfunction at the time of cardiac surgery including their creatinine and urea levels and the hepatic enzyme levels were derived from this database and were then counter-checked from the renal and hepatic transplant registries.

Patients' follow-up for both the transplant and CM groups was completed by medical records including the most recent outpatient clinic visit and was supplemented by the chronology of general practice letters. Finally, each patient was contacted and the follow-up data were cross-checked and supplemented by a set of questionnaire through telephone interviews.

**Statistical analysis**

Descriptive statistics used for continuous variables were mean and standard deviation or median with inter-quartile range (IQR) depending on data distribution. Categorical variables were described with absolute numbers and percentages. For univariate comparisons between treatment groups, \( \chi^2 \) test, Fisher's exact test, unpaired t-test and Wilcoxon rank-sum test were used where appropriate. Kaplan–Meier survival methods and log-rank test were used for survival analyses.

For multivariate comparisons between treatment groups, binary logistics regression and Cox proportional hazard methods were used. Indices of cardiac and functional status (logistic EuroSCORE, NYHA grade, past myocardial infarction, presence of current angina, left ventricular ejection fraction etc.) were included as covariates in multivariate models. For logistic models, odds ratio and 95% confidence interval (95% CI) are described. For survival methods, hazard ratio (HR) and 95% CI are described. All P-values were two-sided, and a P-value of <0.05 was considered significant a priori.

**RESULTS**

**Demographics**

Of all the variables studied in demographics, hypertension was more prevalent in the transplant group 74.85 vs 63.5% (P = 0.05), and renal transplant patients were more hypertensive than liver transplant patients (83 vs 66.7%). Transplant patients were also more likely to be smokers with either current or previous history of smoking (P = 0.03). The rest of the variables were comparable between all groups (Table 2).

**Risk factors for cardiac surgery**

The median (IQR) of the EuroSCORE was comparable between all groups (P = 0.08), but was higher in the transplant recipients when compared with CM (P = 0.045). The comparison of the EuroSCORE distribution between Groups III and IV showed low (25 vs 37.5%), medium (38.9 vs 37.5%) and high risks (36.1 vs 25%), respectively.

**Table 2: Demographics and risk factors for cardiac surgery**

<table>
<thead>
<tr>
<th>Demographic variables</th>
<th>Group 1 renal transplant recipients (N = 30)</th>
<th>Group 2 hepatic transplant recipients (N = 6)</th>
<th>Group 3 all organ recipients (N = 36)</th>
<th>Group 4 matched cohort - non-transplant (N = 104)</th>
<th>P-value all groups</th>
<th>P-value Group 3 vs 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>55.7 ± 11.5</td>
<td>60.7 ± 8.0</td>
<td>56.5 ± 11.0</td>
<td>56.5 ± 11.1</td>
<td>0.65</td>
<td>0.94</td>
</tr>
<tr>
<td>Gender (male), N (%)</td>
<td>22 (73%)</td>
<td>5 (83%)</td>
<td>27 (75%)</td>
<td>78 (75%)</td>
<td>0.93</td>
<td>1.0</td>
</tr>
<tr>
<td>Hypertension, N (%)</td>
<td>25 (83%)</td>
<td>4 (66.7%)</td>
<td>29 (80.6%)</td>
<td>65 (62.5%)</td>
<td>0.08</td>
<td>0.05</td>
</tr>
<tr>
<td>Diabetes</td>
<td>9 (30%)</td>
<td>0 (0%)</td>
<td>6/35 (25%)</td>
<td>25 (24%)</td>
<td>0.60</td>
<td>0.55</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>20 (66.7%)</td>
<td>2 (33.3%)</td>
<td>22 (61.1%)</td>
<td>72 (69.2%)</td>
<td>0.19</td>
<td>0.37</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>12 (40%)</td>
<td>3 (50%)</td>
<td>15 (41.7%)</td>
<td>40 (38.5%)</td>
<td>0.092</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>18 (60%)</td>
<td>3 (50%)</td>
<td>21 (58.3%)</td>
<td>47 (45.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>17 (16.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family history of coronary disease</td>
<td>8 (26.7%)</td>
<td>1 (16.7%)</td>
<td>9 (25%)</td>
<td>42 (40.4%)</td>
<td>0.23</td>
<td>0.10</td>
</tr>
<tr>
<td>History of CVA/TIA</td>
<td>3 (10%); (2 TIA, 1 CVA)</td>
<td>0 (0%)</td>
<td>3 (8.3%)</td>
<td>8 (7.7%); (3 TIA, 5 CVA)</td>
<td>0.32</td>
<td>0.90</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>4 (13.3%)</td>
<td>1 (16.7%)</td>
<td>5 (13.9%)</td>
<td>8 (7.8%)</td>
<td>0.35</td>
<td>0.27</td>
</tr>
<tr>
<td>Respiratory disease (COPD)</td>
<td>6 (20%)</td>
<td>0 (0%)</td>
<td>6 (16.7%)</td>
<td>14 (13.5%)</td>
<td>0.51</td>
<td>0.64</td>
</tr>
<tr>
<td>Previous MI</td>
<td>6 (20.7%)</td>
<td>2 (33.3%)</td>
<td>8 (25.2%)</td>
<td>20 (19.2%)</td>
<td>0.70</td>
<td>0.64</td>
</tr>
</tbody>
</table>

All P-values relate to comparison between characteristics of Groups 1, 2 and 4. COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; TIA: transient ischaemic attack; MI: myocardial infarction.
with $P$-values of 0.27 in all group comparison, while the $P$-value was 0.30 between Groups III and IV.

Clinical risk factors that are known to increase mortality and morbidity in cardiac surgery patients viz. peripheral vascular disease, unstable angina, left main disease; congestive cardiac failure and decreased ejection function were comparable among the various groups and between Groups III and IV (Table 2).

Renal and hepatic variables

Transplant variables. The most common reason for renal transplant was glomerulonephritis (46.7%) followed by reflux nephropathy (23.4%) and polycystic kidney disease (10%). Systemic lupus erythematosus, lead toxicity, diabetes and light-chain nephropathy were other culprits. Cirrhosis was the most common cause of hepatic transplant (33.3%). Other causes were hepatocellular carcinoma, alcoholic liver disease, cholangitis and non steroid analgesic drug hepatopathy. Of the 30 renal transplant patients, 5 were transplanted twice, while 2 were transplanted thrice. All the liver transplant patients received a transplant only once.

Other renal and hepatic variables. Three patients with renal transplants were on dialysis (2 haemodialysis and 1 peritoneal dialysis), preoperatively. No patient in the hepatic transplant group was on dialysis. However, in the case-matched group only, 1 patient was on preoperative dialysis.

Renal and hepatic functions. The perioperative renal functions are depicted in Fig. 1a. As expected, there was a transient allograft dysfunction after cardiopulmonary bypass as demonstrated by the creatinine trends. Similarly, there was a trend towards transient allograft dysfunction in the liver transplant patients (Fig. 1b and c). However, the elevated enzyme levels normalized or tended to normalize to base line levels at discharge. The elevation of liver enzymes in the CM population was absent, but transient elevation of creatinine seen in the CM population was insignificant.

Cardiac surgery variables. Coronary artery bypass graft (CABG) constituted 50% of patients in the transplant group, and 49% in the CM group. Valve repair or replacement comprised 22.2 and 25% patients in the transplant and CM groups, respectively. Similarly, patients with both valve and coronary surgery were 19.4 and 17% in the transplant and control, respectively. The other surgery cohorts had 8.3 and 9% patients in the transplant and CM groups, respectively. The $P$-value between the groups was 0.98. Two patients with renal transplants had redo cardiac surgeries.

Average time from transplant to cardiac surgery was 10.8 ± 7.4 and 4.2 ± 3.0 years in the renal transplant and liver transplant patients, respectively, while the time from cardiac surgery to follow-up was 46.3 (IQR = 20.8–84.1) and 38.9 months (IQR = 14.6–72.3) in the transplant and CM population, respectively ($P$ = 0.25, Table 3).

The cardiopulmonary bypass time in minutes in the transplant group was 67.5 (49.5–120) and in the CM population it was 81.5 (61–110.5) ($P$ = 0.11). Similarly, the cross-clamp times were 44 (28–68.5) minutes in the ASOT cohort and 57.5 (40–81.5) minutes in the CM cohort ($P$ = 0.07). In 4 patients of the transplant group, cardiopulmonary bypass was not used either because it was not needed, e.g. in pericardiectomy, or the operation was done off-pump. LITA was used in 16 patients of the transplant group and 60 in the CM group.

Outcomes data. Follow-up was complete in 100% of the surviving transplant group. The follow-up in the cross-matched group was done in 94 (90.38%) patients. Four of the 10 (9.62%) patients not included in the follow-up in the matched group did not participate.

The follow-up time was $1649 ± 1176$ (4.5 ± 3.2 years) and $1428 ± 1173$ days (3.9 ± 3.2 years) in the transplant cohort and CM population, respectively (Table 3). Significant morbidities are as outlined in Table 4. There was no loss of allograft function in the transplant group, although dialysis was required in 3 (8.3%) patients in the transplant group and in 1 (0.96%) in the cross-matched population ($P$ = 0.049). The patients requiring dialysis recovered their allograft function before discharge. The rate of all infection was 6 (16.66%) and 6 (0.42%) in the ASOT and the CM groups, respectively ($P$ = 0.045). There were 3 patients with leg wound infections who needed antibiotics, 2 had endocarditis and 1 had septicemia and multi-organ failure. However, interestingly, there were no infections recorded in the liver transplant patients. The infection in the CM population was leg wound infection in 5 and unknown in 6. Another important variable demonstrating increased morbidity was the median length of stay, with that in the ASOT group being 6 days (IQR 5.9), whereas in the CM group it was 5 days with an IQR of 4.6 ($P$ = 0.01). The combined major morbidities were overall 11 and 9% in the in the transplant and CM groups, respectively ($P$ = 0.6).

Functional class. More than half of the transplant patients were in NYHA Class III and IV before cardiac surgery, while after the cardiac intervention more than half of the live patients were in Classes I and II. The CM patients were nearly half in Class I and the rest in Class II or III after cardiac surgery.

![Figure 1: (a) Perioperative trends of alanine transaminase in liver transplant patients. (b) Perioperative trends of alkaline phosphatase in liver transplant patients. (c) Perioperative trends of creatinine in renal transplant patients.](image-url)
Mortality

There was no 30-day or ‘in-hospital’ mortality in either group. Late mortality in the transplant group was 8 (22.2%) (Table 5). Interestingly, all late deaths were in the renal transplant patients, making it 8 of 30 (26.6%) in the renal transplant group, while late mortality in the hepatic transplant patients was 0/6 (0%). Infection was the most major cause of late death 5 of 36 (13.88%), with 2 patients developing endocarditis, 2 developing multiorgan failure due to sepsis and 1 developing mediastinitis. One patient each (3.33%) died because of cardiac failure and arrhythmias, while the cause of death in 1 patient could not be ascertained. In contrast, 3 of 104 patients in the CM group died of cardiac causes (2.88%). Three patients died of unrelated causes (1 lung cancer, 1 committed suicide, 1 unidentified cause). The total mortality in the cross-matched group was 6 of 104 (6%) (Table 5). No post-mortem examination results were available in the patients who died.

On multivariate analysis, the predictors of late mortality were increasing age and history of solid organ transplant. Increasing age had HR of 1.1 with 95% CI of 1.04–1.18 and P-value of 0.003. History of solid organ transplant was found to have HR of 3.44, 95% CI of 1.19–9.98 and a P-value of 0.023.

One of the patients who died was on continuous abdominal peritoneal dialysis, the rest of the patients had functioning allografts and all were on immunosuppression. Of 8 patients who died 2 had undergone CABG, 1 isolated valve replacement and 5 had combined CABG and valve replacement.

Survival was calculated using the Kaplan–Meier survival curves. There was a significant diversion in the survival curves at the end of 10 years between the transplant and the CM cohort outlining the increased mortality of allograft recipients. One-, 2-, 5- and 10-year survival rates for ASOT vs CM were 94, 88, 80, 59 vs 99, 99, 91 and 85%, respectively. Multivariate predictors of mortality were increasing age (HR 1.1, 95% CI 1.04–1.18; P = 0.003) and solid organ transplantation (HR 3.44, CI 1.19–9.98; P = 0.023; Fig. 2).

DISCUSSION

Continued analysis of current treatment and management strategies predicts the course of the future direction in the modification of treatment and improvement of outcomes and advises on new directions in research funding and planning. This could not be truer than in the investigation of disease processes in the ever-expanding population of allograft recipients.

End-stage renal disease (ESRD) patients have poor life expectancy, but it has improved since the advent of dialysis [4]. Our previous publication highlights that despite dialysis, the mortality rates in ESRD patients are high, 9.99 deaths per 100 patient years in peritoneal dialysis and 7.96 deaths per 100 patient years in haemodialysis patients [5]. Transplantation confers the highest survival benefit among different renal replacement therapies; however, renal allograft recipients still have a high mortality rate compared with population controls.

It was shown that though renal transplant improves the mortality to an impressive 2.3 per 100 patient years, it is still significantly higher than the matched general population [5]. For example, in one European study, the mortality of the recipients of the first renal transplants was 14 times higher than the age-matched population without renal failure during the first year after transplantation and was four times higher after this period [6].

The incidence of cardiovascular events in transplant recipients including myocardial infarction was as high as 61% within a month of renal transplant [7]. In addition to the short-term increase in morbidity, cardiovascular events are the most common cause of death in functioning renal transplant recipients. In a study by West et al. [8], it was seen that 17% of deaths in renal transplant recipients happened because of myocardial infarction, while about 15% died from arrhythmias. In a more recent study, even the late mortality was ascribed to cardiovascular disease. According to Briggs [9], the most common cause of late mortality after successful renal transplant is cardiovascular disease, accounting for 40-55% of all deaths. The relative risk of ischaemic cardiac

---

**Table 3:** Time intervals between transplant and cardiac surgery and follow-up periods

<table>
<thead>
<tr>
<th>Group 1 renal transplant recipients (N = 30)</th>
<th>Group 2 hepatic transplant recipients (N = 6)</th>
<th>Group 3 all organ recipients (N = 36)</th>
<th>Group 4 matched cohort-non-transplant (N = 104)</th>
<th>P-value all groups</th>
<th>P-value Group 3 vs Group 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time from most recent transplant to cardiac surgery (years)</td>
<td>10.8 ± 7.4</td>
<td>4.2 ± 3.0</td>
<td>10.3 ± 7.2</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Time from cardiac surgery to follow-up months median (inter-quartile)</td>
<td>51.9 (24.0–90.6)</td>
<td>21.7 (8.8–41.3)</td>
<td>46.3 (20.8–84.1)</td>
<td>38.9 (14.6–72.3)</td>
<td>0.06</td>
</tr>
</tbody>
</table>

**Table 4:** Major morbidities

<table>
<thead>
<tr>
<th>Morbidity</th>
<th>Transplant Group 3</th>
<th>Case-match Group 4</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of stay (median)</td>
<td>6 days (IQR 5.9)</td>
<td>5 days (IQR 4.6)</td>
<td>0.01</td>
</tr>
<tr>
<td>Return to theatre</td>
<td>2 (5.5%)</td>
<td>4 (3.8%)</td>
<td>0.765</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>11 (30.5%)</td>
<td>28 (26.9%)</td>
<td>0.515</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>1 (2.7%)</td>
<td>4 (3.8%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Neurological</td>
<td>1 (2.7%)</td>
<td>5 (4.08%)</td>
<td>1.00</td>
</tr>
<tr>
<td>New dialysis</td>
<td>3 (8.3%)</td>
<td>1 (0.96%)</td>
<td>0.049</td>
</tr>
<tr>
<td>Infection</td>
<td>6 (16.6%)</td>
<td>6 (0.42)</td>
<td>0.045</td>
</tr>
<tr>
<td>Allograft loss</td>
<td>0 (0%)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA: not applicable.
increase the risk [10]. The already high-risk pro-
volume and electrolyte imbalance. Proteinuria and anaemia also
transplant [12]. In hepatic transplant patients, 40% have
10% incidence of adverse cardiovascular events after hepatic
in transplant pathophysiology
The dysfunctional organ seems to have been replaced with
another hitherto unnamed ‘surrogate disease’ complex, which
consequently translates into an increased incidence of new car-
diovascular disease as well as exaggerated progression of existing
cardiovascular disease in the transplant patients. Needless to say,
the overwhelming burden of cardiac disease in the fast-
increasing cohort of allograft recipients requires intervention.
Medical therapy, percutaneous intervention and cardiovascular
surgery are all treatment options for these patients.
Cardiovascular surgery can improve the quality of life, but
increased problems with wound healing, infection and allograft
failure are concerns of paramount importance. Interestingly,
cardiovascular surgery as a process in itself is far from physiological
and compounds the problems of existing cardiovascular disease,
new cardiovascular disease, transplant pathophysiology and
post-transplant immunosuppression due to the deleterious
effects of cardiopulmonary bypass. The allograft itself is vulner-
able to surgical injury, ischaemia–reperfusion injury and
systemic inflammatory response consequent to cardiopulmonary
bypass [13].

A study was planned to investigate the complex interplay of
the above-mentioned variables on functioning of the allografts
both in the perioperative period and in the long-term. The
course of cardiovascular disease in post-transplant patients,
freedom from cardiovascular symptoms, re-intervention,
re-hospitalization and their early, mid- and long-term survivals
was studied. This is the first study where outcomes of cardiac
surgery in patients with prior solid organ transplants were com-
pared with the CM population in terms of age, sex and type of
cardiac surgery.

Various groups have investigated the cardiac surgical out-
comes in transplant recipients from 1984 till recently (Table 6).
Most reports have concentrated on renal transplant patients [13],
while others have considered only liver transplants [14] and
some have included pancreatic transplants as well [2, 15]. Our
study investigated both liver and kidney transplant patients.

Again all the studies including ours are retrospective; however,
only one of the studies has compared the outcomes in transplant
patients with those of the general cardiac surgical popula-
tion. The population had not been case-matched and the
compared groups were from different time frames [2]. This study
incorporates a CM population in a ratio of 1:3 from the same
time frames. This study, therefore, provides a level playing field

<table>
<thead>
<tr>
<th>Group 1 renal transplant recipients (N = 36)</th>
<th>Group 2 hepatic transplant recipients (N = 6)</th>
<th>Group 3 all organ recipients (N = 36)</th>
<th>Group 4 matched cohort-non-transplant (N = 104)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up time</td>
<td>1829 ± 1186</td>
<td>1649 ± 1176 (4.5 ± 3.2 years)</td>
<td>1428 ± 1173 (3.9 ± 3.2 years)</td>
</tr>
<tr>
<td>Deaths</td>
<td>8</td>
<td>8/36 = 22.2%</td>
<td>6/104 = 6%</td>
</tr>
<tr>
<td>Cause of death</td>
<td>Infection 5</td>
<td>NA</td>
<td>Cardiac 3</td>
</tr>
<tr>
<td></td>
<td>Cardiac 1</td>
<td></td>
<td>Lung cancer 1</td>
</tr>
<tr>
<td></td>
<td>Arhythmia 1</td>
<td></td>
<td>Suicide 1</td>
</tr>
<tr>
<td></td>
<td>Uncertain 1</td>
<td></td>
<td>Uncertain 1</td>
</tr>
</tbody>
</table>

NA: not applicable.
There was no mortality in hepatic transplant patients.

dyslipidaemia and 60% have systolic hypertension. These
patients have a higher risk of cardiovascular deaths and ischae-
ic events than the age and sex-matched population [4].

The dysfunctional organ seems to have been replaced with
another hitherto unnamed ‘surrogate disease’ complex, which
consequently translates into an increased incidence of new car-
diovascular disease as well as exaggerated progression of existing
cardiovascular disease in the transplant patients. Needless to say,
the overwhelming burden of cardiac disease in the fast-
increasing cohort of allograft recipients requires intervention.
Medical therapy, percutaneous intervention and cardiovascular
surgery are all treatment options for these patients.
Cardiovascular surgery can improve the quality of life, but
increased problems with wound healing, infection and allograft
failure are concerns of paramount importance. Interestingly,
cardiovascular surgery as a process in itself is far from physiological
and compounds the problems of existing cardiovascular disease,
new cardiovascular disease, transplant pathophysiology and
post-transplant immunosuppression due to the deleterious
effects of cardiopulmonary bypass. The allograft itself is vulner-
able to surgical injury, ischaemia–reperfusion injury and
systemic inflammatory response consequent to cardiopulmonary
bypass [13].

A study was planned to investigate the complex interplay of
the above-mentioned variables on functioning of the allografts
both in the perioperative period and in the long-term. The
course of cardiovascular disease in post-transplant patients,
freedom from cardiovascular symptoms, re-intervention,
re-hospitalization and their early, mid- and long-term survivals
was studied. This is the first study where outcomes of cardiac
surgery in patients with prior solid organ transplants were com-
pared with the CM population in terms of age, sex and type of
cardiac surgery.

Various groups have investigated the cardiac surgical out-
comes in transplant recipients from 1984 till recently (Table 6).
Most reports have concentrated on renal transplant patients [13],
while others have considered only liver transplants [14] and
some have included pancreatic transplants as well [2, 15]. Our
study investigated both liver and kidney transplant patients.

Again all the studies including ours are retrospective; however,
only one of the studies has compared the outcomes in transplant
patients with those of the general cardiac surgical popula-
tion. The population had not been case-matched and the
compared groups were from different time frames [2]. This study
incorporates a CM population in a ratio of 1:3 from the same
time frames. This study, therefore, provides a level playing field

![Figure 2: Kaplan-Meier survival estimates: time to all-cause mortality: multivariate predictors of mortality were increasing age (HR 1.1, 95% CI 1.04–1.18, P = 0.003) and solid organ transplantation (HR 3.44, 95% CI 1.19–9.98, P = 0.023).](image-url)
Table 6: Critical comparison of previous studies of cardiac surgery in transplant recipients

<table>
<thead>
<tr>
<th>Investigators</th>
<th>Year</th>
<th>Number of patients/transplant type</th>
<th>Procedures</th>
<th>Perioperative mortality</th>
<th>Long-term survival</th>
<th>Other important points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolman et al. [20]</td>
<td>1984</td>
<td>Renal</td>
<td>CABG, valve</td>
<td>14% Operative</td>
<td>79% Mean 13 months</td>
<td></td>
</tr>
<tr>
<td>De Meyer et al. [18]</td>
<td>1991</td>
<td>Renal</td>
<td>CABG</td>
<td>11%</td>
<td>85% 3 years</td>
<td></td>
</tr>
<tr>
<td>Dresler et al. [21]</td>
<td>1997</td>
<td>Renal</td>
<td>CABG, valve</td>
<td>8.8% Operative</td>
<td>Mean 22 months (1-90)</td>
<td>Total 86%</td>
</tr>
<tr>
<td>Mitraka et al. [16]</td>
<td>1997</td>
<td>Renal, hepatic and thoracic</td>
<td>CABG, valve, great vessel, pericardiectomy TMR</td>
<td>3% (30 days)</td>
<td>Renal 80%</td>
<td>Thoracic 100%</td>
</tr>
<tr>
<td>Prabhakar et al. [14]</td>
<td>1998</td>
<td>Liver</td>
<td>CABG, valve</td>
<td>No 30-day mortality</td>
<td></td>
<td>Follow-up short; Two late deaths: cardiac and infection; Repeat interventions: 2/15 Cardiac follow-up - subjective: doing well and not doing well!! Includes renal transplant after the revascularization as well</td>
</tr>
<tr>
<td>Ferguson et al. [24]</td>
<td>1999</td>
<td>Renal</td>
<td>CABG, PTCA</td>
<td></td>
<td>78%—3 year</td>
<td></td>
</tr>
<tr>
<td>Reddy et al. [22]</td>
<td>2002</td>
<td>Renal</td>
<td>CABG, valve</td>
<td>7.7%</td>
<td>69% Med 38 months</td>
<td></td>
</tr>
<tr>
<td>Ono et al. [15]</td>
<td>2002</td>
<td>Renal</td>
<td>CABG, valve</td>
<td>5.5%</td>
<td>72.2% (kidney)</td>
<td></td>
</tr>
<tr>
<td>Herzog et al. [19]</td>
<td>2004</td>
<td>Renal</td>
<td>CABG</td>
<td>IMA: 5.0%</td>
<td>With IMA: 82.7%</td>
<td></td>
</tr>
<tr>
<td>Deb et al. [23]</td>
<td>2006</td>
<td>Renal and hepatic</td>
<td>CABG, valve</td>
<td>No IMA: 9.4%</td>
<td>Without IMA: 74.4%</td>
<td></td>
</tr>
<tr>
<td>Zhang et al. [13]</td>
<td>2006</td>
<td>Renal</td>
<td>CABG, valve</td>
<td>2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>John et al. [2]</td>
<td>2007</td>
<td>Kidney/kidney-pancreas</td>
<td>CABG, valve</td>
<td>5.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rahmanian et al. [3]</td>
<td>2009</td>
<td>Renal</td>
<td>CABG, valve</td>
<td>3.4%</td>
<td>1 year: 89 ± 6%</td>
<td></td>
</tr>
<tr>
<td>Sharma et al. [17]</td>
<td>2010</td>
<td>Renal</td>
<td>Valve</td>
<td>14%</td>
<td>5 year: 50 ± 14%</td>
<td>Temporary allograft dysfunction described as more than 30% increase in creatinine and bun 11.4% mortality: tissue 15% non-tissue valve</td>
</tr>
</tbody>
</table>

CABG: coronary artery bypass graft; CPB: cardiopulmonary bypass; IMA: internal mammary artery; PCTA: percutaneous transluminal coronary angioplasty; TMR: transmyocardial laser revascularization.
for the comparison between the transplant and the non-transplant population undergoing cardiac surgery. Our study has included all types of cardiac, pericardiac and great vessel surgery like Mitruka et al. [16]. Some of the groups have restricted the study to only valves [17] or only CABG [18, 19]. However, most groups have studied the combined population of CABG and valve patients [13–16, 20–23].

In our series, there was no perioperative mortality in either of the groups. This is in contrast to other studies where the perioperative mortality varied from 1.4 [2], 2 [23], 3 [16], 5 [15] and 8.8 [21] to 14% [1]. However, Prabhakar’s group [14] has also reported no early mortality. We ascribe this to be the result of close cooperation between the cardiac surgical teams, the renal and hepatic transplant physicians, the anaesthesitists and the intensivists, who are available round the clock because of the excellent logistics of a tertiary-care hospital facility.

In our series, the mean age of the patient population was 56 ± 11 years in both the groups with a range of 31.02–74.06 years. Increasing age was found to be an independent predictor of late mortality in our series. It is in consonance with the findings of Sharma et al. [17]. However, in other studies, the independent predictors of mortality were perioperative renal status, mitral valve disease and left ventricular dysfunction [13], cardiopulmonary bypass >180 min, congestive cardiac failure and emergency heart surgery [2]. Again, Sharma et al. [17] found combined mitral and aortic valve surgery and ESRD caused by diabetes mellitus to be independently associated with increased mortality.

The late mortality in our series was 22.2% in the transplant group. Interestingly, all late deaths were in renal transplant patients making it 26.6% for the renal transplant group. This is consistent with the world literature and also consistent with our expectation of high mortality given the increased burden of comorbidities in the transplant population. Interestingly, 62.5% of all late deaths had infective aetiology, which can be ascribed to the immunosuppression and the concomitant systemic steroid therapy. Surprisingly, no incidence of lymphoma was observed contrary to the expectations in people with long-term immunosuppression, though 7 of the 36 transplant recipients reported incidence of recurrent skin cancers. Here, it would be pertinent to point out that either post-mortem examinations were not performed in the patients who died or the results were not available. Though the cause of death was assumed to be known, there could be fallacies in the actual cause of death, which could skew the results. Interestingly, no reference has been made in the relevant world literature about post-mortem examination in the cause of death.

The long-term survival in our series was 94% for the transplant group vs 99% for the CM group at the end of 1 year. It was 88 vs 99% at 2 years, 80 vs 91% at 5 years and 59 vs 85% at the end of 10 years for the transplant and CM groups, respectively. However, it has to be remembered that the follow-up in the CM population was less than the mandatory 95% mark that is important for the accurate comparison of experimental vs control groups. The late survival is marginally better than that reported in the literature [3, 13, 16, 23] and may be attributed to small sample size or better follow-up care by a multidisciplinary team in a tertiary hospital as highlighted earlier. One multivariate analysis again predicted transplant to be an independent risk factor for mid-term and late mortalities. It is interesting to note that there was no early or late mortality in the liver transplant patients. No early mortality in liver transplant patients has also been reported by Prabhakar et al. [14], but late survival has only been reported to be 69 ± 13% by Deb et al. [23].

Seven of the 30 renal transplant patients had new renal failure (19.4%), 3 of these 7 needed dialysis, however, none of them contributed to mortality. These findings correlate with other published reports [2]. This is a pointer to the fact that transplanted organs can manage the perioperative stress. Similar opinions have been voiced by others [16]. There was no acute rejection or allograft loss in our transplant population either perioperatively or in late follow-up. It is pertinent to point out here that our group does not alter the immunosuppression regimen. This is in contrast with other publications where the incidence of allograft loss has been from 15% [23] in renal transplant and 15% in hepatic transplant [23], 23% [16] to 30% [13]. This can be ascribed to our practice of keeping the high perfusion pressure during cardiopulmonary bypass as unit policy. There was transient elevation of liver enzymes and creatinine levels in both the liver and kidney transplant cohorts. The levels of both showed a trend towards normalization or towards preoperative levels at discharge. This finding has allowed us to deduce that daily renal and liver functions are not required unless the immediate postoperative functions are extremely disturbed or otherwise clinically indicated. A similar opinion has been published by others [14]. The immunosuppression was continued even in failed transplant patients on the premise that it will prevent acute rejection—a process that is still possible, despite failed allograft. It also prevents the development of anti human leucocyte antigen antibodies, which will affect the acceptance of allograft should the patient need a repeat transplant [2].

Infection was the most common complication. 16.66% as expected with the burden of immunosuppression and steroid administration. However, we consider that prolonged use of antibiotics is not required and routine prophylaxis is adequate. This is reflected in the fact that 3 patients had minor infections in the early postoperative period, while 3 had major infection late in the postcardiac surgery follow-up and died due to sepsis. Similar results of around 15% have been reported by others [16].

The length of stay in the transplant cohort is a median of 6 days (IQR 5.9), which can be reasonably expected. It is significantly more than that of the matched population statistically, but is shorter than that reported in another study by Ono et al., who reported a length of stay of 8.5 ± 6.9 (3–42 days), we attribute the shorter length of stay to reduced the incidence of postoperative morbidities.

**CONCLUSION**

This study provides a comparative analysis between patients undergoing cardiac surgery after solid organ transplants and a matched group of patients without transplant. Cardiac surgery can be performed in solid organ transplant recipients with early morbidity and mortality comparable with the cross-matched population. This needs modifications in conduct of cardiopulmonary bypass and management of immunosuppression with a dedicated team of transplant physicians. Solid organ transplant emerging as a predictor of late death has never been reported previously. Long-term survival is poor. Infection remains the major cause of late death. We attribute our encouraging results to the multidisciplinary team approach of surgeons, anaesthetists, transplant physicians and intensivists. The key to long-term...
survival is regular follow-up, prevention of infection and early treatment with urgent referral to a facility with suitable logistics. Consequently, patients should be informed in detail during the consent process about the possibility of repeated visits to an appropriately equipped facility. Resources and manpower should be allocated to meet these needs. Post-mortem examinations should be encouraged in all in-hospital mortalities.

Conflict of interest: none declared.

REFERENCES